Home Overview Press Room Blog Publications For Students about us

Biotech & Pharma : Displaying 11-20 of 2122

Disgraced Scientist Clones Dogs, and Critics Question His Intentby Rob SteinNPRSeptember 30th, 2015South Korean company Sooam Biotech – started by “scientific pariah” Hwang Woo Suk – has cloned over 600 dogs for $100,000, but the process works only one-third of the time and is risky.
Gene-edited 'micropigs' to be sold as pets at Chinese instituteby David CyranoskiNature NewsSeptember 29th, 2015The pigs were originally engineered as models for human disease to test expensive drugs in smaller quantities, but the excitement for customizable pets may be serving as a distraction from synthetic biology's more pressing concerns and controversies.
Scientists Find Gene Editing with CRISPR Hard to Resist[quotes Marcy Darnovsky and Pete Shanks]by Cameron ScottHealthlineSeptember 29th, 2015CRISPR, a new technique for editing DNA, is so cheap and easy to use, we may be genetically engineering human embryos before we have time to decide if we should.
Why Some Parents Choose to Have a Deaf Babyby Rich WordsworthMotherboardSeptember 29th, 2015Genetic deafness is one of many conditions that can be screened for using PGD. That’s led to a surprising phenomenon: deaf parents using PGD not to avoid deafness, but to deliberately select for it.
DARPA Gives MIT Lab $32 Million to Program Living Cellsby Alexandra OssolaPopular ScienceSeptember 29th, 2015Synthetic biology lab the Broad Institute Foundry announced a new defense contract to join computer scientists and companies in "chemicals, pharmaceuticals, food, energy, agriculture, and biotechnology," but the work remains vague.
Limits of Responsibility: Genome Editing, Asilomar, and the Politics of Deliberationby J. Benjamin HurlbutHastings Center ReportSeptember 28th, 2015What justifies the notion that CRISPR has caught us off guard or that it is appropriate for experts to retreat into secluded spaces to define the parameters of public debate?
Who has your DNA—or wants itby Jocelyn KaiserScienceSeptember 25th, 2015More and more groups are amassing computer server–busting amounts of human DNA. Science's informal survey found at least 17 biobanks that hold—or plan to hold—genomic data on 75,000 or more people.
Can 23andMe have it all?by Kelly ServickScienceSeptember 25th, 2015Amid 30 recent deals with biotech and pharma companies, 23andMe hired Genentech retiree Richard Scheller who plans to hire 25 scientists in the next year to begin drug development based off the direct-to-consumer genomic database.
New CRISPR Protein Slices through Genomes, Patent Problemsby Antonio RegaladoMIT Technology ReviewSeptember 25th, 2015With patent rights and Nobel Prize announcements pending, Feng Zhang at the Broad Institute reports new CRISPR gene editing enzyme Cpf1 to compete with the hyped CRISPR-Cas9 system.
A $6 Billion Question: Affordability of California's Stem Cell Therapiesby David JensenCalifornia Stem Cell ReportSeptember 23rd, 2015The California stem cell agency will cost taxpayers $6 billion by 2020. But the agency isn't discussing what any therapies are likely to cost, or whether it should focus on affordable treatments.
Displaying 11-20 of 2122  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760